Symbols / CPIX $3.01 -1.63%
CPIX Chart
About
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 45.02M |
| Enterprise Value | 43.42M | Income | -2.84M | Sales | 44.52M |
| Book/sh | 1.66 | Cash/sh | 0.77 | Dividend Yield | — |
| Payout | 0.00% | Employees | 93 | IPO | — |
| P/E | — | Forward P/E | 21.50 | PEG | — |
| P/S | 1.01 | P/B | 1.81 | P/C | — |
| EV/EBITDA | 32.09 | EV/Sales | 0.97 | Quick Ratio | 0.77 |
| Current Ratio | 1.01 | Debt/Eq | 41.48 | LT Debt/Eq | — |
| EPS (ttm) | -0.19 | EPS next Y | 0.14 | EPS Growth | — |
| Revenue Growth | 31.10% | Earnings | 2026-05-05 | ROA | -2.29% |
| ROE | -12.17% | ROIC | — | Gross Margin | 85.02% |
| Oper. Margin | -10.02% | Profit Margin | -6.37% | Shs Outstand | 14.96M |
| Shs Float | 8.64M | Short Float | 2.07% | Short Ratio | 1.00 |
| Short Interest | — | 52W High | 6.27 | 52W Low | 1.85 |
| Beta | -0.54 | Avg Volume | 185.93K | Volume | 131.05K |
| Target Price | — | Recom | None | Prev Close | $3.06 |
| Price | $3.01 | Change | -1.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.93
Latest analyst target
3. DCF / Fair value
$7.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.93
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2019-12-03 | main | B. Riley Securities | — → Buy | $10 |
| 2019-11-18 | main | B. Riley Securities | — → Buy | $9 |
| 2018-08-17 | main | B. Riley Securities | Buy → Buy | $9 |
| 2018-04-17 | init | B. Riley Securities | — → Buy | $9 |
| 2013-04-10 | main | UBS | — → Neutral | $6 |
| 2012-11-12 | main | UBS | — → Neutral | $5 |
| 2012-11-09 | down | Wells Fargo | Outperform → Market Perform | — |
- New site spotlights chemo nausea patch that helps for five days - Stock Titan ue, 17 Mar 2026 13
- Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat Wed, 25 Feb 2026 08
- [ARS] CUMBERLAND PHARMACEUTICALS INC SEC Filing - Stock Titan hu, 12 Mar 2026 21
- Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding - simplywall.st Fri, 06 Feb 2026 08
- Cumberland Pharmaceuticals Stock On Fire: Up 76% With 5-Day Winning Streak - Trefis Fri, 19 Dec 2025 08
- Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales - The Globe and Mail ue, 10 Mar 2026 18
- Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com ue, 03 Mar 2026 08
- Jones James buys Cumberland Pharmaceuticals (CPIX) shares worth $861 - Investing.com Fri, 12 Sep 2025 07
- Cumberland revenue climbs 18% as Talicia, Vibativ and Caldolor expand access - Stock Titan ue, 03 Mar 2026 08
- Cumberland Pharmaceuticals Leads 3 Promising Penny Stocks - simplywall.st ue, 16 Dec 2025 08
- CPIX SEC Filings - Cumberland Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 04 Mar 2026 19
- H. pylori drug Talicia rolls out in U.S. as infection hits 35% of adults - Stock Titan Wed, 25 Feb 2026 08
- All-in-one H. pylori pill Talicia gets major U.S. sales push - Stock Titan Wed, 25 Feb 2026 08
- Cumberland Pharmaceuticals (NASDAQ: CPIX) details 2026 director, pay and auditor votes - Stock Titan Mon, 09 Mar 2026 21
- $8M 2024 Talicia Revenue — Cumberland to Commercialize FDA‑Approved H. pylori, $4M Investment - Stock Titan Mon, 20 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 270 | 799 | — | Purchase at price 2.24 - 4.32 per share. | KAZIMI A. J. | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 270 | 799 | — | Purchase at price 2.24 - 4.32 per share. | JONES JAMES R | Director | — | 2025-12-31 00:00:00 | D |
| 2 | 66 | 202 | — | Purchase at price 2.24 - 4.32 per share. | YOUNG CAROLINE R | Director | — | 2025-12-31 00:00:00 | D |
| 3 | 1916 | 5653 | — | Purchase at price 2.24 - 4.32 per share. | KROGULSKI KENNETH J | Director | — | 2025-12-31 00:00:00 | D |
| 4 | 302 | 664 | — | Purchase at price 1.96 - 2.82 per share. | KAZIMI A. J. | Chief Executive Officer | — | 2025-11-28 00:00:00 | D |
| 5 | 302 | 664 | — | Purchase at price 1.96 - 2.82 per share. | JONES JAMES R | Director | — | 2025-11-28 00:00:00 | D |
| 6 | 75 | 170 | — | Purchase at price 1.96 - 2.82 per share. | YOUNG CAROLINE R | Director | — | 2025-11-28 00:00:00 | D |
| 7 | 2027 | 4420 | — | Purchase at price 1.96 - 2.82 per share. | KROGULSKI KENNETH J | Director | — | 2025-11-28 00:00:00 | D |
| 8 | 299 | 1022 | — | Purchase at price 3.14 - 3.63 per share. | KAZIMI A. J. | Chief Executive Officer | — | 2025-10-31 00:00:00 | D |
| 9 | 299 | 1022 | — | Purchase at price 3.14 - 3.63 per share. | JONES JAMES R | Director | — | 2025-10-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 806.10 | 172.58K | 128.38K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -54.67K | 1.66M | -278.41K | -857.83K |
| TotalUnusualItems | 237.09K | 821.80K | 611.33K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 237.09K | 821.80K | 611.33K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -6.48M | -6.28M | -5.57M | -5.50M |
| ReconciledDepreciation | 6.04M | 5.77M | 5.33M | 4.61M |
| ReconciledCostOfRevenue | 5.29M | 8.40M | 8.86M | 8.58M |
| EBITDA | 182.42K | 2.49M | 332.92K | -857.83K |
| EBIT | -5.86M | -5.62M | -5.00M | -5.46M |
| NetInterestIncome | -271.06K | -381.01K | -487.59K | -71.95K |
| InterestExpense | 605.51K | 667.86K | 586.00K | 98.03K |
| InterestIncome | 334.44K | 286.85K | 98.41K | 26.08K |
| NormalizedIncome | -6.72M | -6.93M | -6.05M | -5.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -6.48M | -6.28M | -5.57M | -3.51M |
| TotalExpenses | 44.30M | 49.11M | 47.72M | 43.66M |
| TotalOperatingIncomeAsReported | -6.43M | -9.55M | -5.70M | -7.68M |
| DilutedAverageShares | 14.06M | 14.30M | 14.56M | 14.90M |
| BasicAverageShares | 14.06M | 14.30M | 14.56M | 14.90M |
| DilutedEPS | -0.46 | -0.44 | -0.38 | -0.24 |
| BasicEPS | -0.46 | -0.44 | -0.38 | -0.24 |
| DilutedNIAvailtoComStockholders | -6.48M | -6.28M | -5.57M | -3.51M |
| NetIncomeCommonStockholders | -6.48M | -6.28M | -5.57M | -3.51M |
| NetIncome | -6.48M | -6.28M | -5.57M | -3.51M |
| MinorityInterests | -36.05K | 51.45K | 79.80K | 95.21K |
| NetIncomeIncludingNoncontrollingInterests | -6.44M | -6.33M | -5.65M | -3.60M |
| NetIncomeDiscontinuousOperations | 0.00 | 1.99M | ||
| NetIncomeContinuousOperations | -6.44M | -6.33M | -5.65M | -5.60M |
| TaxProvision | -22.67K | 45.77K | 68.85K | 34.89K |
| PretaxIncome | -6.47M | -6.28M | -5.58M | -5.56M |
| OtherIncomeExpense | 237.09K | 3.65M | 611.33K | 2.19M |
| OtherNonOperatingIncomeExpenses | 2.83M | 2.19M | ||
| SpecialIncomeCharges | 237.09K | 821.80K | 611.33K | 0.00 |
| OtherSpecialCharges | -237.09K | -821.80K | -611.33K | |
| NetNonOperatingInterestIncomeExpense | -271.06K | -381.01K | -487.59K | -71.95K |
| InterestExpenseNonOperating | 605.51K | 667.86K | 586.00K | 98.03K |
| InterestIncomeNonOperating | 334.44K | 286.85K | 98.41K | 26.08K |
| OperatingIncome | -6.43M | -9.55M | -5.70M | -7.68M |
| OperatingExpense | 37.71M | 43.04M | 38.60M | 34.85M |
| DepreciationAmortizationDepletionIncomeStatement | 4.75M | 8.10M | 5.07M | 4.37M |
| DepreciationAndAmortizationInIncomeStatement | 4.75M | 8.10M | 5.07M | 4.37M |
| Amortization | 4.75M | 8.10M | 5.07M | 4.37M |
| AmortizationOfIntangiblesIncomeStatement | 4.75M | 8.10M | 5.07M | 4.37M |
| ResearchAndDevelopment | 4.82M | 5.83M | 6.69M | 5.68M |
| SellingGeneralAndAdministration | 28.15M | 29.10M | 26.84M | 24.80M |
| SellingAndMarketingExpense | 17.02M | 18.45M | 16.66M | 15.02M |
| GeneralAndAdministrativeExpense | 11.13M | 10.65M | 10.18M | 9.78M |
| OtherGandA | 11.13M | 10.65M | 10.18M | 9.78M |
| GrossProfit | 31.28M | 33.49M | 32.89M | 27.17M |
| CostOfRevenue | 6.59M | 6.07M | 9.12M | 8.81M |
| TotalRevenue | 37.87M | 39.55M | 42.01M | 35.99M |
| OperatingRevenue | 36.54M | 37.51M | 40.68M | 35.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 13.95M | 14.12M | 14.37M | 14.74M |
| ShareIssued | 13.95M | 14.12M | 14.37M | 14.74M |
| TotalDebt | 20.57M | 18.43M | 20.96M | 16.06M |
| TangibleBookValue | 3.97M | 6.08M | 4.76M | 17.98M |
| InvestedCapital | 38.13M | 42.39M | 52.47M | 57.81M |
| WorkingCapital | 4.83M | 7.73M | 17.29M | 26.41M |
| NetTangibleAssets | 3.97M | 6.08M | 4.76M | 17.98M |
| CapitalLeaseObligations | 5.30M | 5.64M | 4.76M | 1.06M |
| CommonStockEquity | 22.85M | 29.60M | 36.27M | 42.81M |
| TotalCapitalization | 33.03M | 42.39M | 52.47M | 57.81M |
| TotalEquityGrossMinorityInterest | 22.55M | 29.26M | 35.97M | 42.60M |
| MinorityInterest | -307.52K | -343.57K | -292.13K | -212.33K |
| StockholdersEquity | 22.85M | 29.60M | 36.27M | 42.81M |
| RetainedEarnings | -23.97M | -17.49M | -11.21M | -5.64M |
| CapitalStock | 46.82M | 47.09M | 47.47M | 48.45M |
| CommonStock | 46.82M | 47.09M | 47.47M | 48.45M |
| TotalLiabilitiesNetMinorityInterest | 53.04M | 52.52M | 56.95M | 41.86M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.42M | 24.53M | 28.37M | 22.58M |
| OtherNonCurrentLiabilities | 250.00K | 274.00K | 131.00K | 224.79K |
| NonCurrentAccruedExpenses | 2.88M | 3.28M | 4.93M | 3.83M |
| NonCurrentDeferredLiabilities | 3.17M | 2.89M | 2.52M | 3.43M |
| LongTermDebtAndCapitalLeaseObligation | 15.12M | 18.08M | 20.79M | 15.09M |
| LongTermCapitalLeaseObligation | 4.94M | 5.30M | 4.59M | 90.02K |
| LongTermDebt | 10.18M | 12.78M | 16.20M | 15.00M |
| CurrentLiabilities | 31.62M | 27.98M | 28.58M | 19.28M |
| OtherCurrentLiabilities | 8.77M | 9.37M | 11.52M | 4.62M |
| CurrentDeferredLiabilities | 207.06K | 220.40K | 614.55K | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 5.46M | 348.09K | 172.91K | 969.68K |
| CurrentCapitalLeaseObligation | 356.51K | 348.09K | 172.91K | 969.68K |
| CurrentDebt | 5.10M | |||
| OtherCurrentBorrowings | 5.10M | |||
| LineOfCredit | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.20M | 1.20M | 1.44M | 1.34M |
| PayablesAndAccruedExpenses | 15.99M | 16.85M | 14.84M | 12.34M |
| CurrentAccruedExpenses | 2.07M | 2.81M | 4.02M | 2.70M |
| Payables | 13.91M | 14.04M | 10.82M | 9.64M |
| AccountsPayable | 13.91M | 14.04M | 10.82M | 9.64M |
| TotalAssets | 75.58M | 81.78M | 92.93M | 84.46M |
| TotalNonCurrentAssets | 39.13M | 46.06M | 47.05M | 38.77M |
| OtherNonCurrentAssets | 13.79M | 15.50M | 10.05M | 12.47M |
| GoodwillAndOtherIntangibleAssets | 18.89M | 23.52M | 31.50M | 24.84M |
| OtherIntangibleAssets | 17.97M | 22.61M | 30.59M | 23.95M |
| Goodwill | 914.00K | 914.00K | 914.00K | 882.00K |
| NetPPE | 6.45M | 7.04M | 5.50M | 1.47M |
| AccumulatedDepreciation | -2.39M | -2.24M | -2.09M | -3.79M |
| GrossPPE | 8.85M | 9.28M | 7.59M | 5.26M |
| Leases | 7.00M | 7.48M | 6.01M | 2.45M |
| MachineryFurnitureEquipment | 1.84M | 1.81M | 1.58M | 2.81M |
| BuildingsAndImprovements | 1.02M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 36.45M | 35.71M | 45.87M | 45.69M |
| OtherCurrentAssets | 2.79M | 3.03M | 3.08M | 3.34M |
| PrepaidAssets | 3.34M | |||
| Inventory | 4.00M | 4.61M | 9.86M | 8.43M |
| InventoriesAdjustmentsAllowances | -11.01M | -12.80M | -7.53M | -9.05M |
| OtherInventories | 126.09K | 149.70K | 168.92K | 164.38K |
| FinishedGoods | 2.90M | 4.65M | 4.32M | 4.94M |
| RawMaterials | 11.98M | 12.62M | 12.90M | 12.37M |
| Receivables | 11.70M | 9.76M | 13.16M | 6.88M |
| AccountsReceivable | 11.70M | 9.76M | 13.16M | 6.88M |
| AllowanceForDoubtfulAccountsReceivable | -1.10M | -600.00K | -600.00K | -300.00K |
| GrossAccountsReceivable | 12.80M | 10.36M | 13.76M | 7.18M |
| CashCashEquivalentsAndShortTermInvestments | 17.96M | 18.32M | 19.76M | 27.04M |
| CashAndCashEquivalents | 17.96M | 18.32M | 19.76M | 27.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -791.90K | 5.64M | 6.38M | 5.99M |
| RepurchaseOfCapitalStock | -579.05K | -740.53K | -1.05M | -1.39M |
| RepaymentOfDebt | -36.00M | -34.89M | -51.70M | -59.00M |
| IssuanceOfDebt | 38.49M | 31.48M | 52.90M | 59.00M |
| CapitalExpenditure | -179.71K | -453.05K | -2.07M | -354.46K |
| InterestPaidSupplementalData | 569.23K | 647.14K | 523.16K | 63.98K |
| IncomeTaxPaidSupplementalData | 15.00K | 108.82K | 3.30K | |
| EndCashPosition | 17.96M | 18.32M | 19.76M | 27.04M |
| BeginningCashPosition | 18.32M | 19.76M | 27.04M | 24.75M |
| ChangesInCash | -357.44K | -1.44M | -7.28M | 2.29M |
| FinancingCashFlow | 196.90K | -7.42M | -2.06M | -3.55M |
| CashFlowFromContinuingFinancingActivities | 196.90K | -7.42M | -2.06M | -3.55M |
| NetOtherFinancingCharges | -1.72M | -3.27M | -2.21M | -2.17M |
| NetCommonStockIssuance | -579.05K | -740.53K | -1.05M | -1.39M |
| CommonStockPayments | -579.05K | -740.53K | -1.05M | -1.39M |
| NetIssuancePaymentsOfDebt | 2.49M | -3.42M | 1.20M | 0.00 |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | -59.00M | |||
| ShortTermDebtIssuance | 59.00M | |||
| NetLongTermDebtIssuance | 2.49M | -3.42M | 1.20M | 0.00 |
| LongTermDebtPayments | -36.00M | -34.89M | -51.70M | -59.00M |
| LongTermDebtIssuance | 38.49M | 31.48M | 52.90M | 59.00M |
| InvestingCashFlow | 57.84K | -105.69K | -13.67M | -501.89K |
| CashFlowFromContinuingInvestingActivities | 57.84K | -105.69K | -13.67M | -501.89K |
| NetOtherInvestingChanges | 237.56K | 347.36K | 1.90M | 52.57K |
| NetInvestmentPurchaseAndSale | 0.00 | -200.00K | ||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | -200.00K | ||
| NetBusinessPurchaseAndSale | 0.00 | -13.50M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -13.50M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -113.25K | -171.78K | -1.97M | -250.93K |
| PurchaseOfIntangibles | -113.25K | -171.78K | -1.97M | -250.93K |
| NetPPEPurchaseAndSale | -66.46K | -281.27K | -102.15K | -103.53K |
| PurchaseOfPPE | -66.46K | -281.27K | -102.15K | -103.53K |
| OperatingCashFlow | -612.19K | 6.09M | 8.45M | 6.34M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 1.99M | ||
| CashFlowFromContinuingOperatingActivities | -612.19K | 6.09M | 8.45M | 4.35M |
| ChangeInWorkingCapital | 1.29M | 4.63M | 10.44M | 8.18M |
| ChangeInOtherCurrentLiabilities | -1.15M | -2.54M | 419.66K | -1.34M |
| ChangeInOtherCurrentAssets | 189.11K | 65.68K | 689.26K | -35.57K |
| ChangeInPayablesAndAccruedExpense | 1.78M | 3.72M | 14.54M | -757.59K |
| ChangeInPayable | 1.78M | 3.72M | 14.54M | -757.59K |
| ChangeInAccountPayable | 1.78M | 3.72M | 14.54M | -757.59K |
| ChangeInInventory | 2.41M | -23.14K | 911.08K | 4.82M |
| ChangeInReceivables | -1.94M | 3.40M | -6.12M | 5.50M |
| ChangesInAccountReceivables | -1.94M | 3.40M | -6.12M | 5.50M |
| OtherNonCashItems | -1.81M | -1.71M | -2.11M | -3.39M |
| StockBasedCompensation | 301.89K | 365.04K | 447.50K | 741.87K |
| AssetImpairmentCharge | 0.00 | 3.34M | 0.00 | |
| DeferredTax | 0.00 | 0.00 | ||
| DeferredIncomeTax | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 6.04M | 5.77M | 5.33M | 4.61M |
| DepreciationAndAmortization | 6.04M | 5.77M | 5.33M | 4.61M |
| AmortizationCashFlow | 5.07M | 4.37M | ||
| AmortizationOfIntangibles | 5.07M | 4.37M | ||
| Depreciation | 6.04M | 5.77M | 5.33M | 235.07K |
| OperatingGainsLosses | 2.69K | 20.26K | -2.19M | |
| NetIncomeFromContinuingOperations | -6.44M | -6.33M | -5.65M | -3.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CPIX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|